309 related articles for article (PubMed ID: 18729003)
1. Mineralocorticoid receptor antagonists and endothelial function.
Maron BA; Leopold JA
Curr Opin Investig Drugs; 2008 Sep; 9(9):963-9. PubMed ID: 18729003
[TBL] [Abstract][Full Text] [Related]
2. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
3. ARAs to the RESCUE.
Kaplan NM
J Am Soc Hypertens; 2016 Mar; 10(3):187-8. PubMed ID: 27408946
[No Abstract] [Full Text] [Related]
4. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
5. Eplerenone: cardiovascular protection.
Brown NJ
Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
[TBL] [Abstract][Full Text] [Related]
6. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
7. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
[TBL] [Abstract][Full Text] [Related]
8. Eplerenone: a selective aldosterone blocker.
Stier CT
Cardiovasc Drug Rev; 2003; 21(3):169-84. PubMed ID: 12931252
[TBL] [Abstract][Full Text] [Related]
9. Pleiotropic actions of aldosterone and the effects of eplerenone, a selective mineralocorticoid receptor antagonist.
Takeda Y
Hypertens Res; 2004 Nov; 27(11):781-9. PubMed ID: 15824460
[TBL] [Abstract][Full Text] [Related]
10. The clinical pharmacology of eplerenone.
Muldowney JA; Schoenhard JA; Benge CD
Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):425-32. PubMed ID: 19379127
[TBL] [Abstract][Full Text] [Related]
11. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
[TBL] [Abstract][Full Text] [Related]
12. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone.
Lainscak M; Pelliccia F; Rosano G; Vitale C; Schiariti M; Greco C; Speziale G; Gaudio C
Int J Cardiol; 2015 Dec; 200():25-9. PubMed ID: 26404748
[TBL] [Abstract][Full Text] [Related]
13. Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans.
Thum T; Schmitter K; Fleissner F; Wiebking V; Dietrich B; Widder JD; Jazbutyte V; Hahner S; Ertl G; Bauersachs J
Eur Heart J; 2011 May; 32(10):1275-86. PubMed ID: 20926363
[TBL] [Abstract][Full Text] [Related]
14. Recent studies with eplerenone, a novel selective aldosterone receptor antagonist.
McMahon EG
Curr Opin Pharmacol; 2001 Apr; 1(2):190-6. PubMed ID: 11714095
[TBL] [Abstract][Full Text] [Related]
15. Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity.
Schäfer N; Lohmann C; Winnik S; van Tits LJ; Miranda MX; Vergopoulos A; Ruschitzka F; Nussberger J; Berger S; Lüscher TF; Verrey F; Matter CM
Eur Heart J; 2013 Dec; 34(45):3515-24. PubMed ID: 23594590
[TBL] [Abstract][Full Text] [Related]
16. [Mineralocorticoid receptor antagonists: inhibition of the renin angiotensin system].
Derer W; Dechend R; Müller DN
MMW Fortschr Med; 2010 Feb; 152(6):48-9. PubMed ID: 20302183
[No Abstract] [Full Text] [Related]
17. Eplerenone--a novel selective aldosterone blocker.
Zillich AJ; Carter BL
Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
[TBL] [Abstract][Full Text] [Related]
18. New treatment option for heart failure patients: eplerenone.
Southworth MR; Cavallari LH
J Cardiovasc Nurs; 2004; 19(6):390-5. PubMed ID: 15529060
[TBL] [Abstract][Full Text] [Related]
19. New therapy update. Inspra (eplerenone tablets).
Kloner RA
Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
[No Abstract] [Full Text] [Related]
20. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
